Niall Martin, Artios CEO
July 27, 2021 02:00 AM EDTUpdated 01:51 PM
Financing

No­var­tis part­ner Ar­tios bags megaround to dri­ve clin­i­cal work on DNA dam­age re­pair fac­tors

Kyle Blankenship

Bio­phar­ma is con­stant­ly on the hunt for the next gen­er­a­tion of tar­get­ed on­col­o­gy drugs to ef­fec­tive­ly wipe out can­cer cells. But to keep those tu­mors …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times